Merus BV MRUS 深 沪

Genmab进入收购药物开发商Merus的深入谈判阶段

　　生物制药公司Genmab （GMAB） 据悉已进入收购荷兰癌症药物开发商Merus （NASDAQ：MRUS） 的深入谈判阶段。今年市值增长60%的Merus预计很快将宣布并购协议。此次收购将增强Genmab的肿瘤产品组合，尽管仍可能出现其他竞标者。 海量资讯、精准解读，尽在新浪财经APP 责任编辑：张俊 SF065

09-29 23:03

Merus N.V. Announces Proposed Public Offering of Common Shares

06-03 20:05

Merus to Present at Upcoming Investor Conferences

<p>Merus N.V has announced that its CEO, Bill Lundberg, M.D., will present at the William Blair 45th Annual Growth Stock Conference on June 3 and the Jefferies Global Healthcare Conference on June 4. Presentations will be available via webcast on the Company's Investors page and archived for limited time post-event.</p>

05-27 12:00

Merus’ Petosemtamab with Pembrolizumab Interim Data Demonstrates Robust Efficacy and Durability in 1L PD-L1+ r/m HNSCC

Merus N.V. reported interim phase 2 trial results for petosemtamab in combination with pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma, showing a 63% overall response rate, 79% 12-month overall survival, and 9 months median progression-free survival. The data will be presented during the 2025 ASCO Annual Meeting. The company will host a conference call on May 22 at 5:30 p.m. ET.

05-22 21:30

B of A Securities Maintains Buy on Merus, Lowers Price Target to $70

B of A Securities analyst Tazeen Ahmad maintains Merus (NASDAQ:MRUS) with a Buy and lowers the price target from $73 to $70.

03-11 00:54

Foundation Medicine and Merus Collaborate on RNA Platform for Targeting Neuregulin 1 Fusion Cancers

Foundation Medicine, Inc. today announced a collaboration to develop Foundation Medicine's RNA platform as a companion diagnostic for Merus N.V.'s (NASDAQ:MRUS) bispecific antibody zenocutuzumab (Zeno) to treat patients with neuregulin 1 fusion (NRG1+) cancer. Zeno is a Biclonics® that utilizes the ...

2024-08-28 19:13